Skip to main content

A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-168 in Subjects with Relapsed or Refractory B-cell Malignancies

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Newave Pharmaceutical, Inc.

Start Date

October 22, 2021

End Date

October 17, 2026
 

Administered By

Duke Cancer Institute

Awarded By

Newave Pharmaceutical, Inc.

Start Date

October 22, 2021

End Date

October 17, 2026